- Home
- PMN vs LYRA Comparison
PMN vs LYRA Comparison
Compare PMN & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMN
- LYRA
- Stock Information
- Founded
- PMN 2004
- LYRA 2005
- Country
- PMN Canada
- LYRA United States
- Employees
- PMN N/A
- LYRA N/A
- Industry
- PMN Pharmaceuticals and Biotechnology
- LYRA Medical/Dental Instruments
- Sector
- PMN Health Care
- LYRA Health Care
- Exchange
- PMN Nasdaq
- LYRA Nasdaq
- Market Cap
- PMN 16.0M
- LYRA 15.0M
- IPO Year
- PMN N/A
- LYRA 2020
- Fundamental
- Price
- PMN $0.99
- LYRA $7.95
- Analyst Decision
- PMN Strong Buy
- LYRA Buy
- Analyst Count
- PMN 3
- LYRA 2
- Target Price
- PMN $4.33
- LYRA $16.00
- AVG Volume (30 Days)
- PMN 21.0M
- LYRA 91.5K
- Earning Date
- PMN 08-07-2025
- LYRA 08-13-2025
- Dividend Yield
- PMN N/A
- LYRA N/A
- EPS Growth
- PMN N/A
- LYRA N/A
- EPS
- PMN N/A
- LYRA N/A
- Revenue
- PMN N/A
- LYRA $1,185,000.00
- Revenue This Year
- PMN N/A
- LYRA N/A
- Revenue Next Year
- PMN N/A
- LYRA $139.18
- P/E Ratio
- PMN N/A
- LYRA N/A
- Revenue Growth
- PMN N/A
- LYRA N/A
- 52 Week Low
- PMN $0.38
- LYRA $3.81
- 52 Week High
- PMN $2.05
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- PMN 67.59
- LYRA 41.08
- Support Level
- PMN $0.77
- LYRA $7.77
- Resistance Level
- PMN $1.59
- LYRA $8.67
- Average True Range (ATR)
- PMN 0.19
- LYRA 0.45
- MACD
- PMN 0.06
- LYRA -0.03
- Stochastic Oscillator
- PMN 50.12
- LYRA 11.32
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.